Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02YUT
|
||||
Former ID |
DIB008476
|
||||
Drug Name |
Estratab
|
||||
Synonyms |
ESE (Esterified Estrogen)
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Approved | [551871] | ||
Company |
Solvay Pharmaceuticals Inc
|
||||
Formula |
C18H19NaO5S
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Estrogen receptor | Target Info | Agonist | [534591], [551871] | |
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Signaling events mediated by HDAC Class II | |||||
Plasma membrane estrogen receptor signaling | |||||
LKB1 signaling events | |||||
Regulation of Telomerase | |||||
ATF-2 transcription factor network | |||||
AP-1 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Validated nuclear estrogen receptor alpha network | |||||
Signaling mediated by p38-alpha and p38-beta | |||||
FOXA1 transcription factor network | |||||
References | |||||
Ref 534591 | Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med. 1997 Dec 8-22;157(22):2609-15. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.